Anti-Aging Drug Reduces Risk Of Age Related Diseases

Senolytic anti-aging drugs are being tested in human after much success in animals such as the Mayo Clinic having 6 human trial underway and are planning to do six more. If trials go according to plan successfully these senolytic anti-aging drugs could be on the market within 2 years.

Clinical geriatrician Dr. James Kirkland of the Mayo Clinic has been quoted as saying “Ageing itself is the highest risk factor for most of the chronic diseases. And if you get one age-related disease, you’ve got a huge chance of having several. You tend to find older individuals who are completely healthy and are playing 18 rounds of golf a day, or they’ve got three, five or 10 different conditions.Therefore, if you targeted fundamental ageing processes it might be possible to delay, prevent or alleviate chronic conditions as a group, instead of going after them one at a time.”

Senolytic anti-aging drugs target senescent zombie cells which accumulate with age caused by the stresses of life that scientists now believe are a critical threshold that trigger disease. Senescent zombie cells were once normal cells that have stopped dividing, these cells don’t die to be cleared away, rather they remain and accumulate while they produce damaging chemical that harm normal healthy cells. Senolytic anti-aging drugs would work to wash away these dysfunctional cells to be replaced by newer cells which can help to slow down the aging process.

“Most people don’t want to live to 130 and feel like they’re 130 but they wouldn’t mind living to 90 or 100 and feel like they’re 60. And now that can actually be achieved in animals.”

The Mayo Clinical is collaborating with 7 other research institutions within the USA to form the Translational Geroscience Network which will conduct the human trials which are urgent to approval of these senolytic anti-aging drugs that have been shown to extend the human equivalent of 30 years to longevity in animal studies.